$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What should you pay attention to when using Pfizer's lorlatinib
2025-10-19 11:44:20
Check Details
What does Pfizer's lorlatinib treat?
2025-10-19 11:44:20
Check Details
Indications of Pfizer's Lorlatinib in the United States
2025-10-19 11:44:20
Check Details
Is ramucirumab from Eli Lilly and Company available in China?
2025-10-19 11:44:20
Check Details
Instructions for Pfizer's Lorlatinib
2025-10-19 11:44:20
Check Details
Is ramucirumab produced by Eli Lilly and Company expensive?
2025-10-19 11:44:20
Check Details
Effects of Pfizer's Lorlatinib in the United States
2025-10-19 11:44:20
Check Details
How effective is American Pfizer's lorlatinib
2025-10-19 11:44:20
Check Details
Dosage and dosage of Pfizer's lorlatinib
2025-10-19 11:44:20
Check Details
Where to buy Pfizer’s Lorlatinib in the United States cheaply
2025-10-19 11:44:20
Check Details
Is the effect of American Ruihui Lorlatinib good?
2025-10-19 11:44:20
Check Details
Is lorlatinib effective?
2025-10-19 11:44:20
Check Details
1
2
...
3718
3719
3720
3721
3722
3723
3724
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
2
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
3
Vemurafenib (Zelboraf) Complete Medication Guide
4
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
5
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
6
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
7
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
8
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
9
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
10
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
11
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
12
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity